The financial authorities are overhauling the disclosure system for pharmaceutical and biotech companies. The focus will shift from future value explanations, such as expectations of clinical success or large technology transfer contracts, to providing investors with concrete figures on success probabilities, development costs, and contract structures.On July 30, the Financial Supervisory Service (FSS) announced a comprehensive improvement plan for pharmaceutical and biotech disclosures aimed at

As international oil prices surge due to the ongoing conflict in the Middle East, inflation continues to rise, resulting in a decline in real wages for workers for the second consecutive month.The Ministry of Employment and Labor reported on July 30 that the nominal wage for employees at businesses with at least one regular worker was 3,982,000 won in May, an increase of 1.7% (66,000 won) compared to the same month last year. This marks four consecutive months of growth since February.However, w

Rokit Healthcare, a regenerative medicine company, is experiencing a surge in stock prices following the announcement of the world's first clinical trials for kidney regeneration.According to the Korea Exchange, as of 9:37 a.m., Rokit Healthcare's shares rose by 5,050 won (13.76%) to 41,750 won. At one point, the stock increased by 22.75%, reaching 45,200 won.The announcement that Rokit Healthcare, in collaboration with a leading general hospital in South Korea, has begun the world's first clini

The Korea Technology Finance Corporation (Kibo) announced on July 30 that it has signed a memorandum of understanding with Hyundai Motor Company, Kia, and the Industrial Bank of Korea to provide financial support for semiconductor companies collaborating with Hyundai and Kia. This agreement aims to enhance financial accessibility for Hyundai and Kia's partner semiconductor firms in response to the global supply chain restructuring and intensified technological competition, while also supporting

Jeong Mong-kyu, the president of the Korea Football Association, and Hong Myung-bo, the former head coach of the national football team, appeared before a National Assembly hearing on July 30, where they expressed regret over the team's poor performance in the 2026 FIFA World Cup.The hearing, conducted by the National Assembly's Culture, Sports and Tourism Committee, was convened in response to growing public criticism following the national team's exit from the group stage of the World Cup. It

Imsil County in North Jeolla Province is taking steps to have the Osu Dog, a native breed that embodies the 'loyal dog folklore,' recognized as a natural monument at the national level.On July 30, the county announced that it recently held a review meeting to assess the application materials for the Osu Dog's designation as a natural monument, discussing future directions and necessary improvements.The Osu Dog is featured in historical texts from the Goryeo Dynasty, such as the 'Bohanjip,' as th

Namwon City in North Jeolla Province is launching a comprehensive and long-term traffic management initiative to ensure smooth traffic flow in the Jirisan National Park Bamsagol area.The plan aims to prevent inconveniences caused by vehicle congestion and illegal parking, especially during the summer vacation season and the autumn foliage period when visitor numbers remain high.According to the city on July 30, the Bamsagol Valley is a 14-kilometer gorge flowing along the northern slope from Ban

In the competitive diabetes treatment market, there is a growing focus on developing next-generation therapies that not only provide cardiovascular and renal protection like existing SGLT-2 inhibitors but also manage postprandial blood sugar levels. In this context, Jeil Pharmaceutical has garnered attention by revealing the Phase 2 clinical trial results for its oral type 2 diabetes drug candidate, JP-2266. On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2

The competition to develop next-generation diabetes treatments that not only provide cardiovascular and kidney protection like existing SGLT-2 inhibitors but also manage post-meal blood sugar levels is intensifying. In this context, Jeil Pharmaceutical has garnered attention by revealing the results of its Phase 2 clinical trial for the oral type 2 diabetes drug candidate JP-2266. On July 30, Jeil Pharmaceutical announced that the results of the Phase 2 study for JP-2266 were published in the in